The management of pain in spasticity

Disability and Rehabilitation

Volumn 24, Issue 8, 2002, Pages 443-453

  Ward, A B ^a   Kadies, M ^a  

^a HAYWOOD HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANALGESIC AGENT; ANTICONVULSIVE AGENT; BACLOFEN; BOTULINUM TOXIN A; BOTULINUM TOXIN B; BUPIVACAINE; CANNABIS; CARBAMAZEPINE; CHLORPROMAZINE; CLONIDINE; CYPROHEPTADINE; DANTROLENE; DIAZEPAM; GABAPENTIN; IVERMECTIN; KETAZOLAM; MEXILETINE; NONSTEROID ANTIINFLAMMATORY AGENT; OPIATE; ORPHENADRINE; PHENOL; PHENYTOIN; SEROTONIN UPTAKE INHIBITOR; SPASMOLYTIC AGENT; TETRAZEPAM; THREONINE; TIZANIDINE; TOCAINIDE; TRICYCLIC ANTIDEPRESSANT AGENT;

ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; DROWSINESS; HUMAN; MEDICAL LITERATURE; MEDICAL RESEARCH; MUSCLE SPASM; MUSCLE WEAKNESS; NAUSEA; NERVE BLOCK; NEUROSURGERY; PAIN; PAIN ASSESSMENT; PATHOPHYSIOLOGY; PHYSICAL MEDICINE; PRIORITY JOURNAL; SIDE EFFECT; SPASTICITY; SYMPTOMATOLOGY; TRANSDERMAL PATCH; TREATMENT PLANNING;

ADMINISTRATION, ORAL; ANALGESICS; BACLOFEN; BOTULINUM TOXINS; HUMANS; INJECTIONS, SPINAL; MUSCLE RELAXANTS, CENTRAL; MUSCLE SPASTICITY; PAIN; RHIZOTOMY;

EID: 0037140660     PISSN: 09638288     EISSN: None     Source Type: Journal    
DOI: 10.1080/09638280110108878     Document Type: Article

References (107)

1. Correlation of knee extensor muscle torque and spasticity with gait speed in patients with stroke
2. Symposium synopsis
3. Spasticity: A review
4. The pathophysiology of spasticity
5. Chronic transformation of muscle in spasticity: A peripheral contribution to increased tone
6. The mechanism of spastic muscle hypertonus: Variation in reflex gain over the time course of spasticity
7. Referred pain of peripheral nerve origin; An alternative to the 'myofascial pain' construct
8. Positive symptoms in Multiple Sclerosis; Their treatment with sodium channel blockers, lidocaine and mexiletine
9. Pain in multiple sclerosis
10. Anatomic correlates of painful tonic spasms in Multiple Sclerosis
11. Understanding and measurement of muscle tone as related to clinical muscle pain
12. Lamotrigine can reduce neurogenic pain associated with Multiple Sclerosis
13. Amelioration of refractory limb pain in Multiple Sclerosis by gabapentin
14. Open label gabapentin treatment for pain in Multiple
15. Physical and occupational therapy considerations in adult patients receiving botulinum toxin injections for spasticity
16. The management of adults with spasticity using botulinum toxin-a guide to clinical practice
17. Management of spasticity
18. Antidepressants and chronic pain
19. Difficult pain problems: ABC of palliative care
20. Antidepressant exacerbation of spasticity
21. Treatment of central pain with gabapentin: Case reports
22. Ketazolam treatment for spasticity: A double-blind study of a new drug
23. Ketazolam once daily for spasticity: A double-blind cross-over study
24. A new skeletal muscle relaxant (DS 103-282) compared to diazepam in the treatment of muscle spasm of local origin
25. Phenytoin and Chlorpromazine in the treatment of spasticity
26. Clonidine in the treatment of brain stem spasticity. A case report
27. Clonidine in the treatment of spasticity in patients with multiple sclerosis
28. Cannabis effect on spasticity in spinal cord injury
29. Tocainide therapy in muscle cramps and spasms due to neuromuscular disease
30. Mexiletine for treatment of spasticity due to neurological disorders
31. Ivermectin for spasticity in spinal-cord injury
32. The effects of cyproheptadine on locomotion and on spasticity in patients with spinal cord injuries
33. Subcutaneous Bupivacaine for treatment of spasticity: A case report
34. Reduction of spastic hypertonia in patients with spinal cord injury: A double blind comparison of intravenous orphenadrine citrate and placebo
35. An antispasticity effect of threonine in multiple sclerosis
36. Mechanisms of tetrazepam action an spasticity
37. Antispasticity drugs: Mechanism of action
38. An evaluation of Baclofen treatment for certain symptoms in patients with spinal cord lesions
39. Baclofen, a new antispastic drug
40. A double-blind comparison of baclofen and placebo in patients with spasticity of cerebral origin
41. Review of European Clinical trials with baclofen
42. Lioresal and spasticity
43. Baclofen-induced memory impairment
44. Nonsurgical therapeutic modalities
45. Complications of baclofen withdrawal
46. Calcium release from skeletal muscle sarcoplasmic reticulum: Site of action of dantrolene sodium?
47. Longterm treatment with dantrolene sodium of stroke patients with spasticity limiting the return of function
48. Drugs for Parkinson's disease, spasticity and acute muscle spasms
49. Molecular mechanisms in the receptor action of benzodiazepines
50. Drug therapy: Spasticity
51. On the site of action of diazepam in spasticity in man
52. A double-blind cross-over trial of Valium in the treatment of spasticity
53. Diazepam effect on reflex activity in patients with complete spinal lesions and in those with other causes of spasticity
54. Comparative profile of tizanidine in the management of spasticity
55. Summary of combined clinical analysis of controlled clinical trials with tizanidine
56. Effect of transdermal clonidine in spinal spasticity. A case series
57. Clonidine transdermal system for treatment of spasticity in spinal cord injury
58. Effect of phenol on conduction and synaptic transmission block
59. Current uses of open phenol nerve block for adult acquired spasticity
60. Treatment of acquired muscle spasticity using phenol peripheral nerve blocks
61. The effectiveness of chemical neurolysis in the treatment of lower limb muscle spasticity
62. The local treatment of spasticity
63. Time course of muscle atrophy and recovery following phenol-induced nerve block
64. Management of the spastic upper extremity in the neurologically impaired adult
65. Percutaneous phenol blocks to motor points of spastic forearm muscles in head-injured adults
66. Botulinum toxin type B (BotB): A double blind placebo controlled safety and efficacy study in cervical dystonia
67. Botulinum toxin F in the treatment of torticollis clinically resistant to botulinum toxin A
68. Botulinum neurotoxin A selectively cleaves the synapse protein SNAP-25
69. Extrafusal and intrafusal muscle effects in experimental Botulinum Toxin-A injection
70. Management of spasticity in cerebral palsy with botulinum A toxin: Report of preliminary, randomised double-blind trial
71. Botulinum toxin in treating spasticity
72. Treatment of spasticity with botulinum toxin: A double-blind study
73. Treatment of spasticity with botulinum toxin
74. Effects of botulinum toxin on spasticity
75. Local botulinum toxin in the treatment of spastic drop foot
76. Botulinum toxin therapy for upper limb flexor spasticity: Preliminary results
77. Effect of treatment with Botulinum toxin on spasticity
78. Treatment of chronic limb spasticity with botulinum toxin A
79. Botulinum toxin A for spasticity, muscles spasms and rigidity
80. Intrathecal phenol to relieve spasticity in paraplegia
81. The treatment of spastic paresis
82. Intrathecal baclofen alleviates spinal cord spasticity
83. Continuous intrathecal baclofen for severe spasticity
84. The use of intrathecal baclofen administered by programmable infusion pumps in persistent spasticity
85. Chronic intrathecal baclofen administration in severe spasticity
86. Intrathecal baclofen for severe spasticity
87. Intrathecal application of baclofen in the treatment of spasticity
88. Intrathecal baclofen for intractable spasticity of spinal origin: Results of a long-term multicenter study
89. Intrathecal Baclofen for treatment of intractable spinal spasticity
90. Implanted pump systems for treatment of spasticity
91. Intrathecal baclofen for long-term treatment of spasticity; A multi-centre study
92. Chronic intrathecal baclofen administration for control of severe spasticity
93. Continuous infusion of intrathecal baclofen: Long-term effects on spasticity in spinal cord injury
94. Effects of intrathecal baclofen on voluntary motor control in spastic paresis
95. Intrathecal baclofen for spasticity in cerebral palsy
96. Use of intrathecal baclofen in familial spastic paraparesis
97. Prospective study on the use of bolus intrathecal baclofen for spastic hypertonia due to acquired brain injury
98. Intrathecal Baclofen administration for control of severe spinal spasticity: Functional improvement and long-term follow-up
99. Intrathecal Baclofen-a multicentre clinical comparison of the Medtronics Programmable Cordis Secor and Constant Infusion Infusaid drug delivery systems
100. Long-term results of posterior functional rhizotomy
101. Selective posterior rhizotomy for the relief of spasticity in cerebral palsy
102. The importance of team work in the treatment of spastic cerebral palsied children undergoing selective posterior rhizotomy
103. Selective posterior rhizotomy for the treatment of spasticity
104. Long-term follow-up of selective dorsal rhizotomy for relief of spasticity in cerebral palsied children
105. Surgery to achieve dynamic motor balance in adult acquired spastic hemiplegia
106. Electromyographic gait analysis before and after operative treatment for hemiplegic equinus and equinovarus deformity